Zacks Investment Research upgraded shares of Alimera Sciences (NASDAQ:ALIM) from a sell rating to a hold rating in a research report released on Monday morning.
According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “
Several other research analysts have also weighed in on the company. HC Wainwright reissued a buy rating and issued a $5.00 price objective on shares of Alimera Sciences in a research report on Friday, October 27th. Cowen reissued a buy rating on shares of Alimera Sciences in a research report on Thursday, November 2nd. Finally, ValuEngine raised Alimera Sciences from a strong sell rating to a sell rating in a research report on Friday, October 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $3.38.
An institutional investor recently raised its position in Alimera Sciences stock. PNC Financial Services Group Inc. boosted its position in Alimera Sciences, Inc. (NASDAQ:ALIM) by 24.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 180,300 shares of the biopharmaceutical company’s stock after buying an additional 35,200 shares during the period. PNC Financial Services Group Inc. owned approximately 0.28% of Alimera Sciences worth $251,000 at the end of the most recent quarter. 41.78% of the stock is currently owned by institutional investors.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Alimera Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alimera Sciences and related companies.